REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase...
Read moreDetails